구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
IL-23p19 (risankizumab). PsO·PsA·IBD. Stelara·Cosentyx와 PASI90·유지·경구 소분자 경쟁.
IL-23 p19 inhibitor (risankizumab-rzaa) for plaque psoriasis, PsA, CD, and UC; selective IL-23 blockade.
기전. Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-23 p19
Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis
Global
Approved
skyrizi · risankizumab-rzaa · Skyrizi · risankizumab · BI 655066
2026-09-10
Data Confidence · High
Development Signal · Established
humanized anti-IL-23 monoclonal antibody, is very effective, with good safety profile and long-term outcomes
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
구조화 데이터
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
IL-17 independent disease and immunogenicity.
humanized anti-IL-23 monoclonal antibody, is very effective, with good safety profile and long-term outcomes
IL-23 p19 · PASI, sPGA, IBD endoscopic scores.
Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22).
immune-mediated chronic skin disease associated with multiple extracutaneous comorbidities, causing a severe quality of life impairment
PASI, sPGA, IBD endoscopic scores.
IL-17 independent disease and immunogenicity.
구조화 데이터
xenografted into these mice
mouse, mouse
28
PASI90/100 rates in pivotal trials
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (psoriasis)
APPROVAL · 2019년 4월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
IL-23p19 (risankizumab). PsO·PsA·IBD. Stelara·Cosentyx와 PASI90·유지·경구 소분자 경쟁.
IL-23 p19 inhibitor (risankizumab-rzaa) for plaque psoriasis, PsA, CD, and UC; selective IL-23 blockade.
기전. Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22).
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-23 p19
Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis
Global
Approved
skyrizi · risankizumab-rzaa · Skyrizi · risankizumab · BI 655066
2026-09-10
Data Confidence · High
Development Signal · Established
humanized anti-IL-23 monoclonal antibody, is very effective, with good safety profile and long-term outcomes
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
구조화 데이터
Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura
IL-17 independent disease and immunogenicity.
humanized anti-IL-23 monoclonal antibody, is very effective, with good safety profile and long-term outcomes
IL-23 p19 · PASI, sPGA, IBD endoscopic scores.
Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22).
immune-mediated chronic skin disease associated with multiple extracutaneous comorbidities, causing a severe quality of life impairment
PASI, sPGA, IBD endoscopic scores.
IL-17 independent disease and immunogenicity.
구조화 데이터
xenografted into these mice
mouse, mouse
28
PASI90/100 rates in pivotal trials
구조화 데이터
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (psoriasis)
APPROVAL · 2019년 4월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.